EDC · LiveBook a demo
All studies
Phase 3RecruitingInterventionalNCT07623161

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib (ELRISE MF)

A Phase 3, Double-Blind, Randomized Trial Evaluating the Efficacy and Safety of Elritercept (TAK-226) Compared to Placebo in Participants With Myelofibrosis and Anemia on Concurrent Ruxolitinib Therapy

  • Myelofibrosis
  • Anemia
I want to take partRefer a patient10 sites in India · 195 worldwide

At a glance

Phase
Phase 3
Study type
Interventional
Sponsor
Takeda
Enrolment target
324
Started
10 September 2026
Main results due (estimated)
7 December 2029
Study ends (estimated)
30 March 2034
Allocation
Randomized
Design
Parallel
Purpose
Treatment
Masking
Triple (participant, care provider, investigator)
Sites
195 · 10 in India
First posted
3 June 2026
Registry updated
1 October 2026

Can you take part?

  • Aged 18 years and over.
  • Open to any sex.
  • You need the condition being studied. Healthy volunteers are not accepted.

Age groups: adult, older adult.

These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.

Read the full eligibility criteria
Inclusion Criteria:

1. Aged ≥18 years at the time of signing the informed consent form (ICF).
2. Able to understand the purpose and risks of the trial and voluntarily sign an ICF.
3. Diagnosed with primary myelofibrosis (PMF), post-essential thrombocythemia (post-ET MF) or post-polycythemia vera (post-PV MF) according to the 2022 WHO criteria (WHO Classification of Tumours Editorial Board 2024), confirmed by local pathology report.
4. Transfusion status as assessed in the 12 weeks immediately preceding randomization classified as Transfusion Dependent: 3 to 8 RBC units over 12 weeks.
5. Receiving ruxolitinib (as approved in the country of the trial site) as the standard of care treatment for MF for at least 12 consecutive weeks, and on a stable daily dose for at least the 8 weeks immediately preceding the date of randomization.
6. Eastern Cooperative Oncology Group score less than or equal to (≤) 2.

Exclusion Criteria:

1. Prior treatment with luspatercept, sotatercept, or other transforming growth factor beta inhibitors or activin receptor ligand traps.
2. Systemic treatment within 28 days before randomization with any of the following:

   1. Androgens (including danazol). Participants on stable androgen dosing for hypogonadism for ≥8 weeks are allowed.
   2. erythropoiesis-stimulating agents.
   3. granulocyte colony stimulating factor or granulocyte-macrophage colony stimulating factor.
   4. High dose corticosteroids. Participants on stable chronic steroid doses of prednisone ≤10 mg/day or corticosteroid equivalent for ≥4 weeks are allowed. Other treatments for autoimmune diseases may be allowed upon medical monitor review.
   5. Hydroxyurea.
   6. Immunomodulatory drugs (for example, thalidomide, pomalidomide, or lenalidomide).
   7. Interferon.
   8. Thrombopoietin receptor agonists.
   9. Any investigational drug, including antihemojuvelin antibody. If the half-life of the investigational product is known, the exclusionary period prior to randomization is equal to 5 half-lives of the investigational product or 28 days, whichever is longer.
3. Initiation of new iron chelation therapy or dose adjustments to existing iron chelation therapy ≤8 weeks prior to randomization. Participants on stable doses of iron chelation therapy for ≥8 weeks are allowed.
4. Clinically significant anemia that is due to causes other than MF or Janus kinase (JAK) inhibitor therapy (for example, thalassemia, iron deficiency, vitamin B12 and/or folate deficiencies, autoimmune or hemolytic anemia, infections, or any active clinically significant bleeding or sequestration).
5. Receipt of RBC transfusion for any reason(s) other than underlying MF within 12 weeks before randomization.
6. Life expectancy \<12 months per investigator's judgment.
7. Clinically significant cardiovascular disease, defined as:

   1. New York Heart Association heart disease Class III or IV;
   2. Fridericia corrected QT interval \>500 millisecond (ms) during screening;
   3. Uncontrolled arrhythmia, myocardial infarction, or unstable angina within 6 months before screening.
8. Uncontrolled hypertension, defined as repeated elevations of systolic blood pressure of ≥160 millimetres of mercury (mmHg) and/or diastolic blood pressure ≥100 mmHg despite adequate treatment.
9. Medical history of thromboembolic events within 6 months before screening, including history of cerebrovascular accident (including ischemic, embolic, and hemorrhagic cerebrovascular accident), transient ischemic attack, deep venous thrombosis (including proximal and distal), pulmonary or arterial embolism, arterial thrombosis, or other venous thrombosis. Participants with prior superficial thrombophlebitis are allowed.
10. Prior history of malignancies, other than MF. Participants who are free of other malignant disease for ≥2 years and have completed treatment, including maintenance, are allowed. Participants with a history or concurrent diagnosis of the following conditions are allowed if not requiring systemic therapy:

    1. Basal or squamous cell carcinoma of the skin;
    2. Carcinoma in situ of the cervix;
    3. Carcinoma in situ of the breast; and/or
    4. Incidental histologic finding of prostate cancer (T1a or T1b using the Tumour, Node, and Metastasis (TNM) staging system);
    5. Early papillary thyroid cancer (stage I \[T1-T2, N0, M0\]).
11. History of solid organ or bone marrow transplantation.
12. Active infection requiring intravenous antibiotics within 28 days or oral antibiotics within 7 days before randomization. Prophylactic antibiotics and/or antifungals for neutropenia are allowed.
13. Known positivity for Human Immunodeficiency Virus (HIV), active hepatitis B virus (HBV), or active hepatitis C virus (HCV). Participants without known history of HIV, HBV, and/or HCV do not require further testing, unless testing is mandated per local guidelines.
14. Body mass index ≥40 kilograms per square meter (kg/m\^2).
15. Major surgery within 28 days before randomization.
16. History of allergy/anaphylaxis to recombinant proteins, investigational product, or excipients (refer to the current elritercept investigator's brochure for a list of excipients), or ruxolitinib.
17. Any of the following local laboratory abnormalities:

    1. Absolute neutrophil count \<500/microliter (μL) (0.5×109/ liter (L)).
    2. Platelet count \<50,000/μL (50×109/L) or \>1,000,000/μL (1000×109/L).
    3. Blasts \>5% as assessed in peripheral blood at screening or ≥10% in any historical bone marrow assessments. Participants with isolated transient elevations of peripheral blood blasts may be eligible after discussion between the investigator and medical monitor to confirm the blast count is not indicative of disease progression.
    4. Serum aspartate aminotransferase or alanine aminotransferase ≥3× the upper limit of normal (ULN).
    5. Total bilirubin ≥2×ULN. Participants with known history of Gilbert syndrome with unconjugated bilirubin less than (\<) 3×ULN are allowed. Higher levels if attributed to active RBC precursor destruction within the bone marrow (ineffective erythropoiesis) may be allowed upon medical monitor review.
    6. Estimated glomerular filtration rate \<30 milliliters per minute per 1.73 square meters (mL/min/1.73 m\^2) as determined by the Chronic Kidney Disease Epidemiology Collaboration equation.
    7. Ferritin ≤50 micrograms per liter (μg/L).
    8. Folate ≤2.0 nanograms per milliliter (ng/mL).
    9. Vitamin B12 ≤200 picograms per milliliter (pg/mL).
18. Ongoing participation in another interventional clinical trial.
19. Participant is unwilling or, in the opinion of the investigator, the participant is unable to comply with the requirements of the protocol.
20. Is a person of childbearing potential but does not agree to use at least 1 form of highly effective contraception from the time of signing the ICF until at least 60 days after the last dose of elritercept or placebo.
21. Participants of male birth who are fertile and who have partners of childbearing potential, who do not agree to use acceptable barrier contraception, that is, a male condom, during the entire treatment period until at least 60 days after the last dose of elritercept or placebo.
22. If applicable, participant with a positive serum pregnancy test during the screening period or known to be pregnant or a lactating participant who does not agree to forego breastfeeding during the entire treatment period until at least 60 days after the last dose of elritercept or placebo.
23. For participants in France: Persons under court protection, persons not affiliated with a social security system, and protected adults.

What this study is about

In the sponsor’s own words, from the registry.

The main aim of this study is to find out how well elritercept works to improve anemia in participants with myelofibrosis (MF) who are taking ruxolitinib when compared to placebo.

Other aims are to learn how elritercept improves anemia compared to placebo; to learn if elritercept reduces tiredness, improves symptoms related to MF, and helps participants do physical activities more easily. The study also aims to find out how elritercept affects the bone marrow, the spleen, and whether participants develop antibodies to the study drug.

The study will also check how safe elritercept is compared to placebo, and if elritercept stays safe over a long period of time. Participants will receive study treatment for at least 9 months (36 weeks). After this period, participants who received placebo will have the option to switch to elritercept.

Keywords: TAK-226 · Drug therapy

What participants receive

  • Experimental

    Elritercept

    Participants will receive elritercept at a starting dose of 3.75 milligrams per kilogram (mg/kg) subcutaneously (SC) once every 4 weeks (Q4W) on Day 1 of each 28-day cycle for approximately 36 weeks during the double-blinded treatment period, with possible up-titration to 5.0 mg/kg from Cycle 3 Day 1 based on response and safety/tolerability. Participants may continue to receive elritercept during the extended open-label treatment period.

    Drug: Elritercept

  • Placebo comparator

    Placebo

    Participants will receive elritercept-matching placebo with equivalent volume to elritercept SC Q4W on Day 1 of each 28-day cycle for approximately 36 weeks during the double-blinded treatment period. Eligible participants may initiate elritercept at a starting dose of 3.75 mg/kg SC Q4W on Day 1 of each 28-day cycle during the extended open-label treatment period, with possible up-titration to 5.0 mg/kg after 2 cycles, based on response and safety/tolerability.

    Drug: Placebo · Drug: Elritercept

Interventions

  • PlaceboDrug

    Elritercept-matching placebo

  • ElriterceptDrug

    Also known as TAK-226

    Elritercept, SC, injection

What the study measures

Primary outcomes

  1. Proportion of Participants Who Are Red Blood Cell-Transfusion Independent (RBC-TI) for Any Consecutive Greater Than or Equal to (≥) 12-Week Period During the 36-Week Double-Blinded Treatment Period

    RBC-TI is defined as no RBC transfusions administered for the specified time period during study treatment.

    Time frame: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)

Secondary outcomes

  1. Proportion of Participants Who Achieve ≥50 Percent (%) Reduction in RBC Transfusion Burden From Baseline Over Any Consecutive 12-Week Period

    Time frame: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)

  2. Proportion of Participants Who Are RBC-TI for Any Consecutive ≥16-Week Period

    RBC-TI is defined as no RBC transfusions administered for the specified time period during study treatment.

    Time frame: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)

  3. Proportion of Participants Who Are RBC-TI for Any Consecutive ≥12-Week Period With Concurrent Mean Hemoglobin (Hgb) Increase ≥1.5 Grams per Deciliter (g/dL) From Baseline

    RBC-TI is defined as no RBC transfusions administered for the specified time period during study treatment.

    Time frame: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)

  4. Proportion of Participants Who Are RBC-TI for Any Consecutive ≥24-Week Period

    RBC-TI is defined as no RBC transfusions administered for the specified time period during study treatment.

    Time frame: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)

  5. Proportion of Participants Who Are RBC-TI for Any Consecutive ≥12-Week Period With Concurrent Mean Hgb Increase of ≥1.0 g/dL and ≥2.0 g/dL From Baseline

    RBC-TI is defined as no RBC transfusions administered for the specified time period during study treatment.

    Time frame: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)

  6. Proportion of Participants Who Are RBC-TI for Any Consecutive 16- or 24-Week Period With a Concurrent Mean Hgb Increase of ≥1.0 g/dL, ≥1.5 g/dL, and ≥2.0 g/dL From Baseline

    RBC-TI is defined as no RBC transfusions administered for the specified time period during study treatment.

    Time frame: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)

  7. Maximum Duration of RBC-TI for Participants Who Achieved RBC-TI for a Consecutive ≥12 Weeks

    RBC-TI is defined as no RBC transfusions administered for the specified time period during study treatment.

    Time frame: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)

  8. Maximum Duration of RBC-TI With Concurrent Mean Hgb Increase of ≥1.5 g/dL for Participants Who Achieved Consecutive ≥12 Weeks RBC-TI With Concurrent Mean Hgb Increase of ≥1.5 g/dL

    RBC-TI is defined as no RBC transfusions administered for the specified time period during study treatment.

    Time frame: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)

  9. Time to Onset of Anemia Response

    Time to onset of anemia response is defined as the duration between the date of randomization and the date participant first achieved anemia response status. Anemia response is evaluated as: achievement of RBC-TI for any consecutive ≥12-week, ≥16-week, or ≥24-week period or ≥50% reduction in red blood cell transfusion burden from baseline over any consecutive 12 weeks.

    Time frame: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)

  10. Mean Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v1.0 - Fatigue 7a T-Score at Week 36

    PROMIS Short Form v1.0 - Fatigue 7a is a 7-item, patient-reported measure designed to assess fatigue symptoms and impact over the past 7 days. Response options are on a 5-point scale from never (1) to always (5). Raw scores are computed by summing responses to all 7 items and then converted to a standardized T-score on a scale from 0 to 100 with a mean of 50 and SD of 10 with higher scores representing worse fatigue. T-scores can be produced using a conversion table available from the instrument developer or using response pattern scoring performed by the Health Measures Scoring Service.

    Time frame: Baseline, Week 36

  11. Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Fatigue Scale Score at Week 36

    EORTC QLQ-C30 is a 30-item, participant-reported multidomain questionnaire designed to assess functioning, wellbeing, and symptom experience of participants with cancer. The questionnaire's items are divided among 5 multi-item scales measuring functioning (physical, role, emotional, cognitive, and social), 3 multi-item scales measuring symptoms (fatigue, nausea/vomiting, and pain), 6 items measuring symptoms (dyspnea, insomnia, appetite loss, constipation, and diarrhea) as well as financial difficulties, and a 2-item scale measuring global health status (GHS))/quality of life (QoL). Items included in GHS/QoL scale use a 7-point response metric ranging from very poor to excellent, while other items use a 4-point response metric with categories including not at all, a little, quite a bit, and very much. Scale scores are transformed to range from 0 to 100 with higher scores indicating better functioning, GHS/QoL, or worse symptomatology.

    Time frame: Baseline, Week 36

  12. Proportion of Participants With Meaningful Improvement and Meaningful Deterioration in PROMIS Short Form v1.0 - Fatigue 7a T-score

    PROMIS Short Form v1.0 - Fatigue 7a is a 7-item, patient-reported measure designed to assess fatigue symptoms and impact over the past 7 days. Response options are on a 5-point scale from never (1) to always (5). Raw scores are computed by summing responses to all 7 items and then converted to a standardized T-score on a scale from 0 to 100 with a mean of 50 and SD of 10 with higher scores representing worse fatigue. T-scores can be produced using a conversion table available from the instrument developer or using response pattern scoring performed by the Health Measures Scoring Service. Score cutoffs to define meaningful improvement and meaningful deterioration will be determined prior to the primary analysis based on analysis of blinded trial data in accordance with a prespecified psychometric analysis plan.

    Time frame: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)

  13. Time to Meaningful Improvement and Meaningful Deterioration in PROMIS Short Form v1.0 - Fatigue 7a T-Score From Baseline

    PROMIS Short Form v1.0 - Fatigue 7a is a 7-item, patient-reported measure designed to assess fatigue symptoms and impact over the past 7 days. Response options are on a 5-point scale from never (1) to always (5). Raw scores are computed by summing responses to all 7 items and then converted to a standardized T-score on a scale from 0 to 100 with a mean of 50 and SD of 10 with higher scores representing worse fatigue. T-scores can be produced using a conversion table available from the instrument developer or using response pattern scoring performed by the Health Measures Scoring Service. Score cutoffs to define meaningful improvement and meaningful deterioration will be determined prior to the primary analysis based on analysis of blinded trial data in accordance with a prespecified psychometric analysis plan.

    Time frame: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)

  14. Proportion of Participants With Meaningful Improvement and Meaningful Deterioration in EORTC QLQ-C30 Fatigue Scale Score

    EORTC QLQ-C30 is a 30-item, participant-reported multidomain questionnaire designed to assess functioning, wellbeing, and symptom experience of participant with cancer. The items are divided among 5 multi-item scales measuring functioning (physical, role, emotional, cognitive, and social), 3 multi-item scales measuring symptoms (fatigue, nausea/vomiting, pain), 6 items measuring symptoms (dyspnea, insomnia, appetite loss, constipation, diarrhea) as well as financial difficulties, and a 2-item scale measuring GHS and QoL. Items included in GHS/QoL scale use a 7-point response metric ranging from very poor to excellent, while other items use a 4-point response metric, categories including not at all, a little, quite a bit, and very much. Scale scores are transformed to range from 0 to 100 with higher scores indicating better functioning, better GHS/QoL, or worse symptomatology. Score cutoffs to define meaningful improvement/deterioration to be determined before primary analysis.

    Time frame: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)

  15. Time to Meaningful Improvement and Meaningful Deterioration in EORTC QLQ-C30 Fatigue Scale Score From Baseline

    EORTC QLQ-C30 is a 30-item, participant-reported multidomain questionnaire designed to assess functioning, wellbeing, and symptom experience of participant with cancer. The items are divided among 5 multi-item scales measuring functioning (physical, role, emotional, cognitive, social), 3 multi-item scales measuring symptoms (fatigue, nausea/vomiting, pain), 6 items measuring symptoms (dyspnea, insomnia, appetite loss, constipation, diarrhea) as well as financial difficulties, and a 2-item scale measuring GHS and QoL. Items included in GHS/QoL scale use a 7-point response metric ranging from very poor to excellent, while other items use a 4-point response metric, categories including not at all, a little, quite a bit, and very much. Scale scores are transformed to range from 0 to 100 with higher scores indicating better functioning, better GHS/QoL, or worse symptomatology. Score cutoffs to define meaningful improvement/deterioration to be determined before primary analysis.

    Time frame: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)

  16. Mean Changes From Baseline in Myelofibrosis Symptom Assessment Form (MFSAF) v4.0 7-Item Total Symptom Score at Week 36

    MFSAF v4.0 is a unidimensional measure assessing 7 core MF symptoms: fatigue, night sweats, itching, abdominal discomfort, pain under ribs, early satiety, and bone pain. The questionnaire asks participants to rate each symptom at its worst during the past 7 days on a 0 to 10 numeric rating scale ranging from absent (0) to worst imaginable (10). The Total Symptom Score (TSS) is calculated as the average of the 7 individual item responses multiplied by 7, yielding a score range of 0 to 70 with higher scores representing worse symptom severity.

    Time frame: Baseline, Week 36

  17. Proportion of Participants Achieving Confirmed 50% Reduction in MFSAF v4.0 Total Symptom Score (TSS50)

    MFSAF v4.0 is a unidimensional measure assessing 7 core MF symptoms: fatigue, night sweats, itching, abdominal discomfort, pain under ribs, early satiety, and bone pain. The questionnaire asks participants to rate each symptom at its worst during the past 7 days on a 0 to 10 numeric rating scale ranging from absent (0) to worst imaginable (10). The TSS is calculated as the average of the 7 individual item responses multiplied by 7, yielding a score range of 0 to 70 with higher scores representing worse symptom severity.

    Time frame: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)

  18. Time to Symptom Response in MFSAF TSS50 From Baseline

    MFSAF v4.0 is a unidimensional measure assessing 7 core MF symptoms: fatigue, night sweats, itching, abdominal discomfort, pain under ribs, early satiety, and bone pain. The questionnaire asks participants to rate each symptom at its worst during the past 7 days on a 0 to 10 numeric rating scale ranging from absent (0) to worst imaginable (10). The TSS is calculated as the average of the 7 individual item responses multiplied by 7, yielding a score range of 0 to 70 with higher scores representing worse symptom severity.

    Time frame: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)

  19. Mean Change From Baseline EORTC QLQ-C30 Physical Functioning Scale Score at Week 36

    EORTC QLQ-C30 is a 30-item, participant-reported multidomain questionnaire designed to assess functioning, wellbeing, and symptom experience of participant with cancer. The questionnaire's items include 5 multi-item scales measuring functioning (physical, role, emotional, cognitive, and social). These items use a 4-point response metric with categories including not at all, a little, quite a bit, and very much. Scale scores are transformed to range from 0 to 100 with higher scores indicating better functioning.

    Time frame: Baseline, Week 36

  20. Proportion of Participants With Meaningful Improvement and Meaningful Deterioration in EORTC QLQ-C30 Physical Functioning Scale Score

    EORTC QLQ-C30 is a 30-item, participant-reported multidomain questionnaire designed to assess functioning, wellbeing, and symptom experience of participant with cancer. The questionnaire's items include 5 multi-item scales measuring functioning (physical, role, emotional, cognitive, and social). These items use a 4-point response metric with categories including not at all, a little, quite a bit, and very much. Scale scores are transformed to range from 0 to 100 with higher scores indicating better functioning. Score cutoffs to define meaningful improvement and meaningful deterioration will be determined prior to the primary analysis based on analysis of blinded trial data in accordance with a prespecified psychometric analysis plan.

    Time frame: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)

  21. Time to Meaningful Improvement and Meaningful Deterioration in EORTC QLQ-C30 Physical Functioning Scale Score From Baseline

    EORTC QLQ-C30 is a 30-item, participant-reported multidomain questionnaire designed to assess functioning, wellbeing, and symptom experience of participant with cancer. The questionnaire's items include 5 multi-item scales measuring functioning (physical, role, emotional, cognitive, and social). These items use a 4-point response metric with categories including not at all, a little, quite a bit, and very much. Scale scores are transformed to range from 0 to 100 with higher scores indicating better functioning. Score cutoffs to define meaningful improvement and meaningful deterioration will be determined prior to the primary analysis based on analysis of blinded trial data in accordance with a prespecified psychometric analysis plan.

    Time frame: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)

  22. Proportion of Participants With Platelet Response During the 36-Week Double-Blinded Treatment Period

    Platelet response includes a mean increase of ≥30×10\^9/ liter (L) from baseline, a \>50% increase from baseline with a count ≥50×10\^9/L, and conversion from \<100 to ≥100×10\^9/L, each sustained for ≥12 weeks.

    Time frame: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)

  23. Proportion of Participants Achieving Spleen Volume Reduction (SVR) From Baseline as Measured by Computed Tomography/Magnetic Resonance Imaging (CT/MRI) During the 36-Week Double-Blinded Treatment Period

    Proportion of participants achieving SVR of ≥10%, ≥25%, or ≥35% will be presented for this outcome measure.

    Time frame: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)

  24. Proportion of Participants Who Develop Accelerated Phase (AP) MF

    Time frame: Up to approximately 7 years

  25. Time to Progression in Participants Who Develop AP MF

    Time frame: Up to approximately 7 years

  26. Proportion of Participants Who Develop Blast Phase (BP) MF

    Time frame: Up to approximately 7 years

  27. Time to Progression in Participants Who Develop BP MF

    Time frame: Up to approximately 7 years

  28. Plasma Concentration-Time Data for Participants Treated With Elritercept

    Time frame: At multiple time points from Cycle 1 Day 1 (each cycle is 28 days) up to approximately 7 years

  29. Proportion of Participants Treated With Elritercept who Have Antidrug Antibodies

    Time frame: At multiple time points from Cycle 1 Day 1 (each cycle is 28 days) up to approximately 7 years

  30. Overall Survival (OS)

    OS is defined as the time from randomization to the date of death due to any cause.

    Time frame: From randomization to 7 years

Who is running it

Lead sponsor
Takeda
Sponsor type
Industry
Responsible party
The sponsor
Organisation
Takeda
Data monitoring committee
Yes
US FDA-regulated drug
Yes
US FDA-regulated device
No
Sponsor's study ID
TAK-226-3002
Other IDs
2026-525660-17-00

  • Study Director

    Study director

    Takeda

Study sites(195)

  • Medanta- The Medicity- Gurugram

    Gurgaon, Haryana, India

    Not yet recruiting

  • Amrita Institute of Medical Sciences

    Kochi, Kerala, India

    Not yet recruiting

  • Regional cancer Centre

    Thiruvananthapuram, Kerala, India

    Not yet recruiting

  • Sahyadri Super Speciality Hospital Deccan

    Pune, Maharashtra, India

    Not yet recruiting

  • All India Institute of Medical Science

    New Delhi, National Capital Territory of Delhi, India

    Not yet recruiting

  • Rajiv Gandhi Cancer Institute and Research Centre

    Rohini, NEW Delhi, India

    Not yet recruiting

  • Apollo Specialty Hospitals

    Chennai, Tamil Nadu, India

    Not yet recruiting

  • Apollo Hospital Hyderabad

    Hyderabad, Telangana, India

    Not yet recruiting

  • Tata Medical Center, Kolkata

    Kolkata, West Bengal, India

    Not yet recruiting

  • Max Super Specialty Hospital

    Delhi, India

    Not yet recruiting

  • Advanced Research, LLC

    Coral Springs, Florida, United States

    Recruiting

  • LUMI Research

    Houston, Texas, United States

    Recruiting

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona, United States

    Not yet recruiting

  • Los Angeles Cancer Network

    Glendale, California, United States

    Not yet recruiting

  • Cancer and Blood Specialty Clinic

    Whittier, California, United States

    Not yet recruiting

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia, United States

    Not yet recruiting

  • Bioresearch Partners

    Miami, Florida, United States

    Not yet recruiting

  • AdventHealth - Cancer Institute - Orlando

    Orlando, Florida, United States

    Not yet recruiting

  • Florida Clinical Trials Group

    Tamarac, Florida, United States

    Not yet recruiting

  • Moffit Cancer Center

    Tampa, Florida, United States

    Not yet recruiting

  • Emory University

    Atlanta, Georgia, United States

    Not yet recruiting

  • Tufts Medical Center

    Boston, Massachusetts, United States

    Not yet recruiting

  • Washington University School of Medicine

    St Louis, Missouri, United States

    Not yet recruiting

  • St. Vincent Regional Hospital Cancer Centers

    Billings, Montana, United States

    Not yet recruiting

  • University of New Mexico Comprehensive Cancer Center

    Albuquerque, New Mexico, United States

    Not yet recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

    Not yet recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York, United States

    Not yet recruiting

  • Duke Blood Cancer Center

    Durham, North Carolina, United States

    Not yet recruiting

  • Novant Health

    Winston-Salem, North Carolina, United States

    Not yet recruiting

  • Cleveland Clinic

    Cleveland, Ohio, United States

    Not yet recruiting

  • Oregon Health and Science University

    Portland, Oregon, United States

    Not yet recruiting

  • Thomas Jefferson University

    Philadelphia, Pennsylvania, United States

    Not yet recruiting

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, United States

    Not yet recruiting

  • Allegheny Health Network Cancer Institute - West Penn Hospital Location

    Pittsburgh, Pennsylvania, United States

    Not yet recruiting

  • Medical University of South Carolina

    Charleston, South Carolina, United States

    Not yet recruiting

  • Vanderbilt-Ingram Cancer Center (VICC)-Nashville

    Nashville, Tennessee, United States

    Not yet recruiting

  • Baylor University Medical Center

    Dallas, Texas, United States

    Not yet recruiting

  • MD Anderson Cancer Center

    Houston, Texas, United States

    Not yet recruiting

  • The University of Utah-Huntsman Cancer Institute

    Houston, Texas, United States

    Not yet recruiting

  • University of Washington

    Seattle, Washington, United States

    Not yet recruiting

Showing 40 of 195 sites, filter to narrow it down. 2 of 195 on this study are recruiting right now, and 10 are in India. A site can stop enrolling while the study as a whole is still open.

References and data sharing

Participant data shared
Yes
What is shared
Study protocol, Sap, Icf, Csr
Access
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Source: ClinicalTrials.gov record NCT07623161, status verified September 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Take part

Interested in this study?

Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.

A person reads this, not a bot. We are not doctors, this is not medical advice, and it is not for emergencies.

Not the right study?

Every study recruiting in India, one search away.

Back to the catalogue
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib | Trialion